To Evaluate Improvement Effect of Subjective Symptoms of Mucotra SR Tablet in Patients With Gastritis
Launched by DAEWOONG PHARMACEUTICAL CO. LTD. · Oct 30, 2024
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men or women aged ≥ 19 years
- • Subjects with acute or chronic gastritis, requiring treatment with Mucotra® SR tab
- • Subjects with subjective symptoms
- • Subjects who voluntarily consent to participate in this observational study
- Exclusion Criteria:
- • Subjects who have had a hypersensitivity reaction to the components of Mucotra® SR tab
- • Subject with genetic disorders such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
About Daewoong Pharmaceutical Co. Ltd.
Daewoong Pharmaceutical Co., Ltd. is a leading South Korean biopharmaceutical company committed to advancing healthcare through innovative research and development. With a strong focus on the discovery and commercialization of novel therapeutics, Daewoong specializes in a diverse range of therapeutic areas, including gastroenterology, endocrinology, and neurology. The company is dedicated to improving patient outcomes by leveraging cutting-edge technology and scientific expertise, and it actively engages in global clinical trials to bring new treatments to market. Daewoong's commitment to quality and innovation positions it as a key player in the pharmaceutical industry, striving to enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wonju, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported